WIA
GYRE icon

Wetzel Investment Advisors’s Gyre Therapeutics GYRE Stock Holding History

Wetzel Investment Advisors’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-266
Closed -$7K – 1075
2023
Q4 		$7K Buy
+266
New +$3.77K ﹤0.01% 606

Other funds holding GYRE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wetzel Investment Advisors's GYRE Position: Q1 2024 in Review

Wetzel Investment Advisors sold out of Gyre Therapeutics (GYRE) in Q1 2024, closing a stake of 266 shares — an estimated $7K sold.

Wetzel Investment Advisors first reported a position in GYRE in Q4 2023 and held it in 1 quarter. The position peaked at $7K in Q4 2023. 21 funds tracked by Wall St. Rank hold GYRE as of Q1 2024.

  • Wetzel Investment Advisors reported no remaining Gyre Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Wetzel Investment Advisors sold 266 Gyre Therapeutics shares in Q1 2024, an estimated $7K.
  • Wetzel Investment Advisors first reported a position in Gyre Therapeutics in Q4 2023 and held it in 1 quarter.
  • Wetzel Investment Advisors's Gyre Therapeutics position peaked at $7K in Q4 2023.
  • 21 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2024.

Based on Wetzel Investment Advisors's 13F filing for Q1 2024, filed 23 Apr 2024.